ARTHEx Biotech: Funding, Investors & Team (Sep 2026)
In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun off from the University of Valencia in Spain, conducts research and develops innovative oligonucleotide treatments that control microRNA. In order to produce exploratory miR-modulating oligonucleotides that are intended to enter pertinent tissues in pharmacological quantities and treat disorders in which microRNAs play a significant role, ARTHEx has created its own technology, the ENTRY TM platform. ATX-01, an antimiR for Myotonic Dystrophy Type 1 that is in preclinical development, is the first experimental medicine from this technology (DM1) More than 900,000 people worldwide suffer from DM1, an orphan disease for which there is currently neither a cure nor an approved treatment.
ARTHEx Biotech has raised $93.9M across 4 funding rounds on record, the most recent a Series B of $40.6M announced in Sep 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ARTHEx Biotech Company Profile and Key Stats
Latest funding round on record: Sep 2025.
ARTHEx Biotech Funding Rounds
ARTHEx Biotech raised $4.3M in an undisclosed round announced in Jul 2020.
2.3 years later, an undisclosed round of $2.5M was announced in Nov 2022.
6 months later, a Series B of $46.5M was announced in May 2023.
2.3 years later, a Series B of $40.6M was announced in Sep 2025.
ARTHEx Biotech Founders and Leadership Team
Contact details for the ARTHEx Biotech team: 2 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →ARTHEx Biotech Funding Compared to Other Biotechnology Startups
ARTHEx Biotech's latest round of $40.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ARTHEx Biotech in Biotechnology and Valencia
Companies Similar to ARTHEx Biotech
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of…
ARTHEx Biotech Funding FAQs
What does ARTHEx Biotech do?
In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun off from the University of Valencia in Spain, conducts research and develops innovative oligonucleotide treatments that control microRNA. In order to produce exploratory miR-modulating oligonucleotides that are intended to enter pertinent tissues in pharmacological quantities and treat disorders in which microRNAs play a significant role, ARTHEx has created its own technology, the ENTRY TM platform. ATX-01, an antimiR for Myotonic Dystrophy Type 1 that is in preclinical development, is the first experimental medicine from this technology (DM1) More than 900,000 people worldwide suffer from DM1, an orphan disease for which there is currently neither a cure nor an approved treatment.
How much funding has ARTHEx Biotech raised?
ARTHEx Biotech has raised $93.9M across 4 rounds on record. The most recent is a Series B of $40.6M announced in Sep 2025.
When did ARTHEx Biotech last raise funding?
ARTHEx Biotech's most recent funding round on record is a Series B of $40.6M, announced in Sep 2025.
Who is the CEO of ARTHEx Biotech?
Beatriz Llamusi is listed as CEO at ARTHEx Biotech.
Where is ARTHEx Biotech headquartered?
ARTHEx Biotech is based in Valencia, Comunidad Valenciana, Spain.
How many employees does ARTHEx Biotech have?
ARTHEx Biotech is in the 11-50 employee band.
How does ARTHEx Biotech's funding compare to other Biotechnology startups?
ARTHEx Biotech's latest round of $40.6M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ARTHEx Biotech Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ARTHEx Biotech is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.